Logo image of IGMS

IGM BIOSCIENCES INC (IGMS) Stock Fundamental Analysis

NASDAQ:IGMS - Nasdaq - US4495851085 - Common Stock - Currency: USD

1.34  -0.04 (-3.25%)

After market: 1.34 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to IGMS. IGMS was compared to 566 industry peers in the Biotechnology industry. IGMS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. IGMS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

IGMS had negative earnings in the past year.
In the past year IGMS has reported a negative cash flow from operations.
IGMS had negative earnings in each of the past 5 years.
IGMS had a negative operating cash flow in each of the past 5 years.
IGMS Yearly Net Income VS EBIT VS OCF VS FCFIGMS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

IGMS has a worse Return On Assets (-73.69%) than 67.49% of its industry peers.
IGMS's Return On Equity of -406.45% is on the low side compared to the rest of the industry. IGMS is outperformed by 76.86% of its industry peers.
Industry RankSector Rank
ROA -73.69%
ROE -406.45%
ROIC N/A
ROA(3y)-58.31%
ROA(5y)-50.05%
ROE(3y)-201.55%
ROE(5y)-138.68%
ROIC(3y)N/A
ROIC(5y)N/A
IGMS Yearly ROA, ROE, ROICIGMS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IGMS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IGMS Yearly Profit, Operating, Gross MarginsIGMS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K

More info and screens

6

2. Health

2.1 Basic Checks

IGMS does not have a ROIC to compare to the WACC, probably because it is not profitable.
IGMS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for IGMS has been increased compared to 5 years ago.
IGMS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IGMS Yearly Shares OutstandingIGMS Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
IGMS Yearly Total Debt VS Total AssetsIGMS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

IGMS has an Altman-Z score of -6.83. This is a bad value and indicates that IGMS is not financially healthy and even has some risk of bankruptcy.
IGMS has a worse Altman-Z score (-6.83) than 66.78% of its industry peers.
There is no outstanding debt for IGMS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.83
ROIC/WACCN/A
WACC9.92%
IGMS Yearly LT Debt VS Equity VS FCFIGMS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M 300M

2.3 Liquidity

IGMS has a Current Ratio of 5.14. This indicates that IGMS is financially healthy and has no problem in meeting its short term obligations.
IGMS has a Current ratio (5.14) which is in line with its industry peers.
IGMS has a Quick Ratio of 5.14. This indicates that IGMS is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 5.14, IGMS perfoms like the industry average, outperforming 57.07% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.14
Quick Ratio 5.14
IGMS Yearly Current Assets VS Current LiabilitesIGMS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 32.64% over the past year.
Looking at the last year, IGMS shows a very strong growth in Revenue. The Revenue has grown by 25.72%.
EPS 1Y (TTM)32.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.6%
Revenue 1Y (TTM)25.72%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-36.71%

3.2 Future

Based on estimates for the next years, IGMS will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.78% on average per year.
IGMS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 33.27% yearly.
EPS Next Y66.84%
EPS Next 2Y33.9%
EPS Next 3Y20.19%
EPS Next 5Y11.78%
Revenue Next Year119.87%
Revenue Next 2Y79.68%
Revenue Next 3Y61.2%
Revenue Next 5Y33.27%

3.3 Evolution

IGMS Yearly Revenue VS EstimatesIGMS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5M 10M 15M
IGMS Yearly EPS VS EstimatesIGMS Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -1 -2 -3 -4 -5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

IGMS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IGMS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IGMS Price Earnings VS Forward Price EarningsIGMS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IGMS Per share dataIGMS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as IGMS's earnings are expected to grow with 20.19% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.9%
EPS Next 3Y20.19%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IGMS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IGM BIOSCIENCES INC

NASDAQ:IGMS (5/1/2025, 9:09:33 PM)

After market: 1.34 0 (0%)

1.34

-0.04 (-3.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-06 2025-03-06/amc
Earnings (Next)05-08 2025-05-08/amc
Inst Owners59.9%
Inst Owner Change0%
Ins Owners4.57%
Ins Owner Change0.51%
Market Cap80.11M
Analysts50.77
Price Target1.91 (42.54%)
Short Float %2.88%
Short Ratio4.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.4%
Min EPS beat(2)-23.77%
Max EPS beat(2)18.96%
EPS beat(4)2
Avg EPS beat(4)-488.19%
Min EPS beat(4)-1950.05%
Max EPS beat(4)18.96%
EPS beat(8)6
Avg EPS beat(8)-240.76%
EPS beat(12)9
Avg EPS beat(12)-161.84%
EPS beat(16)13
Avg EPS beat(16)-120.29%
Revenue beat(2)2
Avg Revenue beat(2)45.95%
Min Revenue beat(2)2.58%
Max Revenue beat(2)89.31%
Revenue beat(4)2
Avg Revenue beat(4)-10.42%
Min Revenue beat(4)-97.74%
Max Revenue beat(4)89.31%
Revenue beat(8)2
Avg Revenue beat(8)-25.4%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-13.04%
PT rev (3m)-90.5%
EPS NQ rev (1m)-2.5%
EPS NQ rev (3m)20.65%
EPS NY rev (1m)-9.67%
EPS NY rev (3m)53.46%
Revenue NQ rev (1m)24.47%
Revenue NQ rev (3m)-7.4%
Revenue NY rev (1m)-5.52%
Revenue NY rev (3m)-2.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 29.9
P/FCF N/A
P/OCF N/A
P/B 1.66
P/tB 1.66
EV/EBITDA N/A
EPS(TTM)-3.24
EYN/A
EPS(NY)-1.07
Fwd EYN/A
FCF(TTM)-2.66
FCFYN/A
OCF(TTM)-2.56
OCFYN/A
SpS0.04
BVpS0.81
TBVpS0.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -73.69%
ROE -406.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-58.31%
ROA(5y)-50.05%
ROE(3y)-201.55%
ROE(5y)-138.68%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 64.22%
Cap/Sales 218.44%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.14
Quick Ratio 5.14
Altman-Z -6.83
F-Score4
WACC9.92%
ROIC/WACCN/A
Cap/Depr(3y)127.25%
Cap/Depr(5y)475.26%
Cap/Sales(3y)584.64%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.6%
EPS Next Y66.84%
EPS Next 2Y33.9%
EPS Next 3Y20.19%
EPS Next 5Y11.78%
Revenue 1Y (TTM)25.72%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-36.71%
Revenue Next Year119.87%
Revenue Next 2Y79.68%
Revenue Next 3Y61.2%
Revenue Next 5Y33.27%
EBIT growth 1Y26.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year79.78%
EBIT Next 3Y22.7%
EBIT Next 5YN/A
FCF growth 1Y22.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.41%
OCF growth 3YN/A
OCF growth 5YN/A